Andre Tomlin

Profile photo of Andre Tomlin
André Tomlin is an Information Scientist with 20 years experience working in evidence-based healthcare. He's worked in the NHS, for Oxford University and since 2002 as Managing Director of Minervation Ltd, a consultancy company who do clever digital stuff for charities, universities and the public sector. Most recently André has been the driving force behind the Mental Elf and the National Elf Service; an innovative digital platform that helps professionals keep up to date with simple, clear and engaging summaries of evidence-based research. André is a Trustee at the Centre for Mental Health and an Honorary Research Fellow at University College London Division of Psychiatry. He lives in Bristol, surrounded by dogs, elflings and lots of woodland!

Website

Follow me here –

  • Badge_support
  • Badge_stat
  • Badge_creative

Can hypnosis help prevent postnatal depression?

shutterstock_29258065

The short answer is we don’t know, but trials are underway that might help answer this question. Postnatal depression often affects women in the first 3 months after giving birth and symptoms can range from low mood and loss of interest in daily activities to thoughts of suicide. There are a range of effective treatments [read the full story…]

New Dutch guideline seeks to reduce unnecessary prescribing of antidepressants to people with depressive symptoms

shutterstock_104286563

I don’t normally blog about non-English language publications, but this new evidence-based guideline from the Dutch College of General Practitioners caught my eye yesterday. The guidance says that antidepressants should only be given as a first line treatment to people with severe depression and that those who only have depressive symptoms should be given a [read the full story…]

LSE report highlights ‘massive inequality’ in the way the NHS treats mental illness compared to physical illness

shutterstock_56306071

Mental illness accounts for nearly half of all ill health in people under 65, but only a quarter of people are given the treatment they need, according to a new report published today by the London School of Economics. The report has been written by a distinguished group of mental health and health policy professionals from [read the full story…]

Updated substance misuse guidelines from the British Association for Psychopharmacology

shutterstock_52270387

Psychiatrists, GPs and other professionals working in the substance misuse field will benefit from reading these new guidelines from the British Association for Psychopharmacology. The guidelines cover the pharmacological management of alcohol, nicotine, opioids, benzodiazepines, stimulants and associated comorbidity with mental health problems and substance use or abuse in pregnancy. They look specifically at comorbidity, [read the full story…]

End of life care for people with dementia: new research briefing from SCIE

shutterstock_90826127

End of life care is an emotive subject and perhaps none more so than in people with dementia where it can be particularly difficult to ensure that individuals get the care they want in the final months of their life. Both the Department of Health and NICE have published guidance in this area and this [read the full story…]

Prescriptions for alcohol dependency increase once more, but attitudes to drinking are on a downward trend

shutterstock_26260609

The NHS Information Centre have published their annual series of reports about alcohol use and misuse.  The reports cover a range of issues including drinking habits and behaviours among adults (aged 16 and over) and school children (aged 11 to 15), drinking-related ill health and mortality, affordability of alcohol, alcohol related admissions to hospital and alcohol-related [read the full story…]

Omega-3 fish oil supplements don’t help with cognitive decline or dementia in the short-term, according to new Cochrane review

shutterstock_55385059

Fish oil supplements are big business. The worldwide omega-3 market has recently been valued at around $5 billion with 40% growth predicted between 2010 and 2015. Omega-3 fatty acids are fats responsible for many important jobs in the body. We get these fats through our daily diets and the three major omega-3 fats are: Alpha [read the full story…]

Extrapyramidal side effects from second-generation antipsychotic drugs: new systematic review

shutterstock_45290365

The newer second-generation antipsychotic drugs (Risperidone, Quetiapine, Amisulpride, Aripiprazole, Clozapine, Olanzapine) are promoted because they have a lower risk of extrapyramidal side effects than older drugs. Drug companies often promote these newer drugs as virtually free from extrapyramidal side effects, but the patients who take them and the clinicians who prescribe them often don’t agree. [read the full story…]

Here is the evidence for exercising if you are depressed

shutterstock_42861211

Ooh, what a palaver over the depression and exercise story!  Such a lot of words have been written about the study published in the BMJ last week, including by me. The study itself was well conducted but frankly disappointing (for us readers and the researchers themselves), finding as it did that a specific treatment to [read the full story…]

Secretin should not be used to treat autism spectrum disorders

shutterstock_3347646

In 1998 a very small study was published, involving just 3 children with autism, who were treated with a hormone called secretin that controls digestion. Here’s the abstract of the study by Horvath et al: We report three children with autistic spectrum disorders who underwent upper gastrointestinal endoscopy and intravenous administration of secretin to stimulate [read the full story…]